JUST IN: Positive topline results from our Phase 3 BROOKLYN study of obicetrapib, our investigational CETP inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH). https://bit.ly/3LKFu3M
NewAmsterdam Pharma Corporation
Biotechnology
Aventura, Florida 7,556 followers
NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases.
About us
This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.
- Website
-
https://www.newamsterdampharma.com
External link for NewAmsterdam Pharma Corporation
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- Aventura, Florida
- Type
- Public Company
- Founded
- 2019
Locations
-
Primary
Aventura, Florida, US
Employees at NewAmsterdam Pharma Corporation
Updates
-
27% of young adults had elevated LDL-C, according to a 2021 study, increasing their risk of cardiovascular disease later in life. The National Heart, Lung, and Blood Institute recommends a lipid panel as early as age 2 if there is a family history of high cholesterol, heart attack, or stroke. https://bit.ly/3Ajf4Ue
-
-
We’re pleased to share some of our recent accomplishments, corporate updates, and financial results for the second quarter and first half of 2024. https://bit.ly/3ytTZWF
-
-
For people with heterozygous familial hypercholesterolemia (HeFH), a lifetime of high LDL-C can lead to early-onset cardiovascular disease including heart attacks and strokes. Our CEO Dr. Michael Davidson explains why we selected HeFH—a tough-to-treat condition–for our first Phase 3 clinical trial.
-
Statins alone aren’t enough to get many people to their LDL-C goals. As Prof. Stephen Nicholls notes, we need additional lipid-lowering therapy options to help reduce the global burden of cardiovascular disease.
-
In a survey of nearly 1,200 patients presented at #ACC24, oral lipid-lowering therapies were “significantly more preferred to all injectable regimens.” We continue to advance our pipeline of investigational oral options for lowering LDL-C. https://bit.ly/3YkENFN
-
-
Understanding your family’s history with cholesterol, and the connections between lipids and cardiovascular disease, is immensely important, as the Gradney family’s story highlights. Read about their 8-year journey to an FH diagnosis. Family Heart Foundation https://bit.ly/4bZjn4e
-
-
We’re excited to announce the addition of two new members to our Board of Directors: Mark McKenna and Wouter Joustra. These appointments bring valuable expertise to our Board in pharmaceutical industry leadership and life sciences investments as we approach pivotal Phase 3 data readouts from multiple clinical trials. https://bit.ly/3y5nvSl We’d also like to thank Sander Slootweg, who is departing the Board, for his significant contributions and dedication.
-
-
“FH is much more common than we once thought...” -- Dr. Joshua Knowles Familial hypercholesteremia (FH) affects 1 in every 220 people across all ages and ethnic backgrounds. As you’ll hear in this American Heart Association podcast, that’s at least 1.3 million Americans and as few as 10% have been properly diagnosed. https://bit.ly/4f87bkA
-